Talmapimod
- Generic Name
- Talmapimod
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30ClFN4O3
- CAS Number
- 309913-83-5
- Unique Ingredient Identifier
- B1E00KQ6NT
- Background
Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
- Indication
Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
Phase 2
Completed
- Conditions
- Bone Marrow DiseasesMyelodysplastic SyndromesHematologic DiseasesBone Marrow Neoplasms
- Interventions
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00113893
Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2010-10-22
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00095680
SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
- First Posted Date
- 2004-08-20
- Last Posted Date
- 2010-10-18
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT00089921
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2010-10-18
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00087867
Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2002-08-14
- Last Posted Date
- 2010-04-27
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT00043732
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath